Do Care Facilities Offer Cannabis for Disruptive Behaviours in Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Agitation, aggression, and restlessness can be among the most distressing symptoms of dementia for families and care teams alike. As medical cannabis becomes more widely discussed in the UK, some people wonder if it can be offered in care facilities to calm disruptive behaviours. According to NHS and NICE guidance, the answer is no, cannabis is not currently authorised or routinely offered for this purpose.

Current UK Position

Cannabis-based medicinal products (CBPMs) are legal in the UK only under specialist prescription and remain Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001.

According to NHS England, CBPMs can be prescribed only for specific conditions such as multiple sclerosis spasticity, severe epilepsy, and chemotherapy-related nausea. Dementia does not qualify as a recognised indication.

Care homes and supported-living settings must comply with the CQC Controlled Drugs Annual Report 2024, which requires all controlled medicines to be prescribed, documented, and stored under strict regulations. This means facilities cannot independently offer cannabis to manage behavioural symptoms.

Clinical Evidence and Guidance

Evidence on cannabinoids for behavioural symptoms in dementia remains limited. A 2024 review in Age and Ageing found that CBD-dominant oils may slightly reduce anxiety and sleep disturbance, but the data were too small and inconsistent to support widespread use (Age and Ageing, 2024).

Similarly, the Alzheimer’s Society states there is insufficient evidence to recommend cannabis for agitation, aggression, or other behavioural changes in dementia.

NICE guidance NG97 specifically advises that cannabinoids should not be used to treat behavioural or psychological symptoms of dementia outside research trials. Instead, staff are encouraged to use behavioural therapies, environmental adjustments, and communication-based support.

Ethical And Safety Considerations

Any cannabis use in dementia care must comply with the Mental Capacity Act 2005, ensuring informed consent or best-interest decisions. Covert administration i.e. giving cannabis without consent is illegal without multidisciplinary approval.

Facilities must also train staff to recognise sedation, confusion, or falls risk when controlled drugs are administered. The CQC and NHS Controlled Drugs Accountable Officer frameworks require ongoing documentation and review.

Clinical Bottom Line

UK care facilities cannot offer cannabis for disruptive behaviour in dementia.

CBPMs are allowed only under specialist prescription for approved conditions.

Behavioural therapies and person-centred care remain first-line approaches.

Research into cannabinoid use for agitation is ongoing but not yet conclusive.

Educational Context: AlleviMed

AlleviMed provides educational information about regulated medical cannabis use in the UK. It explains how eligibility, dosing, and legal frameworks operate for controlled medicines, helping families understand the current limits on cannabis use in care facilities.

Takeaway

Cannabis is not offered in UK care facilities for managing disruptive behaviours in dementia. While research continues, NICE and NHS guidance emphasise non-drug behavioural interventions as the safest and most effective way to support comfort and dignity in care settings.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.